The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.
AuthorsYanik GA, Ho VT, Levine JE, White ES, Braun T, Antin JH, Whitfield J, Custer J, Jones D, Ferrara JL, Cooke KR,
JournalBlood
PubMed ID18664626
'Idiopathic pneumonia syndrome (IPS) refers to a diffuse, noninfectious, acute lung injury after hematopoietic stem cell transplantation. Historically, IPS is associated with respiratory failure and mortality rates exceeding 50%. Preclinical studies have implicated tumor necrosis factor-alpha as an important effector molecule in the development of disease. We studied the tumor ... More